Introduction

Wilson disease (WD) remains a complex genetic disorder characterized by excessive copper accumulation, primarily affecting the liver and brain. Current therapies focus on copper chelation, but neurological symptoms often persist or worsen. Recent experimental evidence suggests that polydatin Wilson disease treatment strategies could offer a novel neuroprotective approach. This natural compound, derived from Polygonum cuspidatum, demonstrates significant potential in protecting neural stem cells from copper-induced toxicity. By targeting specific molecular pathways, polydatin helps maintain cellular integrity in the presence of toxic metal levels.

Mechanism of Polydatin in Wilson Disease

A recent study utilized bioinformatics and experimental models to explore how polydatin intervenes in the pathology of WD. Specifically, the researchers employed Atp7b knockout neural stem cells to simulate the genetic environment of the disease. Consequently, they found that polydatin significantly enhances cell viability and reduces apoptosis in these models. The treatment also successfully restored mitochondrial membrane potential, which usually collapses under copper stress. Furthermore, polydatin treatment decreased the levels of intracellular malondialdehyde and ferrous iron, indicating a reduction in oxidative damage.

Ferroptosis and PPARG Regulation

The study highlights ferroptosis as a major driver of neural damage in copper-overload conditions. This iron-dependent form of cell death involves significant lipid peroxidation. However, the data shows that polydatin mitigates this process by regulating the Peroxisome Proliferator-Activated Receptor Gamma (PPARG) pathway. Researchers observed that polydatin increases the expression of PPARG and glutathione peroxidase 4 (GPX4). Simultaneously, it downregulates long-chain acyl-CoA synthetase 4 (ACSL4), which is a key promoter of ferroptosis. These molecular shifts demonstrate the efficacy of polydatin Wilson disease treatment in stabilizing the cellular antioxidant defense system.

Clinical Implications for WD Management

These findings suggest that adjunct therapies targeting ferroptosis could supplement traditional chelation protocols. While chelation removes excess copper, neuroprotective agents like polydatin might actively repair or prevent ongoing cellular damage. Therefore, this mechanism provides a promising lead for future pharmacological developments in managing the neurological manifestations of Wilson disease. Doctors and researchers are increasingly looking at multi-target natural compounds to bridge the gap in current WD clinical outcomes.

Frequently Asked Questions

How does polydatin reduce copper toxicity in the brain?

Polydatin reduces toxicity by inhibiting ferroptosis, a specific type of cell death driven by iron and lipid peroxidation. It strengthens the antioxidant defense through the PPARG pathway.

What is the significance of the Atp7b gene in this study?

The Atp7b gene is responsible for copper transport. Mutations in this gene cause Wilson disease. Knocking out this gene in stem cells allows researchers to accurately model the disease's effects on the nervous system.

Can polydatin replace current Wilson disease medications?

Currently, polydatin is being studied as a potential adjunct therapy. It is not a replacement for standard copper-chelating agents or zinc therapy prescribed by medical professionals.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Wang N et al. [Polydatin attenuates high copper induced damage in Atp7b knockout neural stem cells by regulating PPARG mediated ferroptosis]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2026 Jun 08. doi: 10.3724/zdxbyxb-2025-0807. PMID: 42260313.